Today: 20 May 2026
BMNR stock today: MSCI backs off crypto-treasury index ban as BitMine’s share-vote clock ticks
8 January 2026
2 mins read

BMNR stock today: MSCI backs off crypto-treasury index ban as BitMine’s share-vote clock ticks

New York, January 8, 2026, 08:03 EST — Premarket

  • BMNR was down about 1% in early premarket trading after a two-session pullback.
  • MSCI said it will not proceed, for now, with a plan to remove crypto-treasury firms from its global indexes.
  • BitMine shareholders have a Jan. 14 deadline to vote on a charter change that would raise the company’s authorized shares.

Shares of BitMine Immersion Technologies (BMNR) were down 1.2% at $30.01 in premarket trading on Thursday, after MSCI said it would not proceed with a proposal to exclude crypto-treasury companies from its indexes. BMNR slid 6.1% on Wednesday to close at $30.36, after a 3.1% drop a day earlier. 

The MSCI decision matters for a small but loud corner of the market: listed firms that hold large piles of bitcoin or ether and often raise money by selling stock. Index inclusion can broaden ownership, but it also puts the spotlight on dilution when those companies keep issuing shares.

MSCI said the proposal to exclude “digital asset treasury companies” from the MSCI Global Investable Market Indexes would not be implemented at the February 2026 index review, and it plans a broader consultation on “non-operating companies” instead. For now, MSCI said it will keep the current index treatment for firms on its preliminary list, but it will not implement increases to the “number of shares” and other inclusion factors it uses to set index weights, and it will defer additions or size-segment migrations for those names. MSCI

BitMine sits in the middle of that debate. The company describes itself as a bitcoin and ethereum network firm, with business lines that include mining and advisory work alongside a balance-sheet strategy focused on accumulating crypto for long-term investment. 

In an update on Monday, BitMine said it held about 4.14 million ether tokens and total crypto and cash of $14.2 billion as of Jan. 4, and it flagged a coming shareholder meeting. Chairman Thomas “Tom” Lee said the company needs a higher authorized-share count “primarily to allow the company to selectively issue shares for capital market activities” and to accommodate future stock splits and potential acquisitions. SEC

A proxy filing shows the company plans to hold its annual meeting on Jan. 15 in Las Vegas, with telephone and internet voting set to close at 11:59 p.m. ET on Jan. 14. One of the proposals seeks approval for a charter amendment to increase authorized common shares — the legal ceiling on how much stock a company can issue. 

Crypto prices were softer ahead of the U.S. open, a headwind for treasury-style names that tend to trade as leveraged proxies for the underlying tokens. Ether was down about 3.7% and bitcoin was off about 2.3%, while Strategy — the best-known crypto-treasury stock — was up about 2.5% in premarket trading.

The open question is what comes next after the reprieve. MSCI’s consultation framework had pointed to the February 2026 review as the point when any rule changes could have landed, and MSCI has now said it wants a broader rethink of how non-operating companies should be treated. 

For BMNR holders, the risk is straightforward: an approved share increase can give the company room to sell more stock, which may dilute existing investors if demand does not keep up, while another leg down in crypto prices would test sentiment quickly. The next catalyst is the Jan. 14 voting deadline ahead of the Jan. 15 meeting, with traders also watching for any further MSCI updates and the next big swing in ether.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
EV Stocks Mixed in Premarket: Rivian Rises Despite Recall as Tesla, Lucid Slip
Previous Story

EV Stocks Mixed in Premarket: Rivian Rises Despite Recall as Tesla, Lucid Slip

Dow Jones Today: Dow steadies near record highs as jobs report looms and Trump defense talk jolts stocks
Next Story

Dow Jones Today: Dow steadies near record highs as jobs report looms and Trump defense talk jolts stocks

Go toTop